Mary Ann Melnick

Yale Cancer Center — United States

Medicine · Health Sciences

11h-index2.1kcitations161works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(139), RNA modifications and cancer(58), Cytokine Signaling Pathways and Interactions(40), Colorectal Cancer Treatments and Studies(28), Synthesis and biological activity(20)

Publications161 total

Epigenetic priming promotes tyrosine kinase inhibitor resistance and oncogene amplification
Nature Structural & Molecular Biology·2025Open Access
Epigenetic priming promotes acquisition of tyrosine kinase inhibitor resistance and oncogene amplification in human lung cancer
2025· 2 citedOpen Access
Table S3 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
Figure S4 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
Figure S1 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
Figure S2 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
Table S3 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
Figure S1 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
Table S4 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
Figure S6 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
Table S2 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
Figure S8 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
Figure S3 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
Figure S6 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
Figure S8 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
Figure S5 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
Table S1 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
Table S2 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
Table S4 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
Table S1 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024Open Access
page 1 of 9Next →

Frequent Co-authors

Katerina Politi(49), Scott Gettinger(30), Anna Wurtz(30), Zenta Walther(30), Jungmin Choi(23), Guoping Cai(23), Andrew Xiao(22), Robert Homer(21), Bomiao Hu(21), Fernando J. de Miguel(20), Qin Yan(20), Don X. Nguyen(20), Marc Wiesehöfer(19), Zongzhi Liu(19), Lok-Hei Chan(19), Anna Arnal Estape(19), Dejian Zhao(19), Francesc López‐Giráldez(19), Rong Fan(19), Sarah B. Goldberg(13)